

**Cumulative Compound Index**

September 2003—August 2004

[Volume 46, Part 10—Volume 47, Part 9 *inclusive*]

Compound	Year	Vol	Part	Pages
<b>A</b>				
Adenosine-A <sub>1</sub> receptor ligand, [Se-75] labelled	2004	47	7	415–427
L-Alanine, [3-C-13], asymm. synth.	2004	47	1	91–94
<i>N</i> -Alkyloxy-6-{5-(4-alkoxyamidinophenyl) furan-2-yl}nicotinamide, [H-2]	2004	47	4	233–242
Amides, $\alpha$ -C-deuteration of, through enolates	2003	46	11	1033–1053
Amides, [carbonyl-C-11], microwave-enhanced synth.	2003	46	13	1249–1259
6-{5-(4-Amidinophenyl)furan-2-yl}nicotinamide, [H-2]	2004	47	4	233–242
(1 <i>R</i> ,2 <i>S</i> ,4 <i>R</i> ,5 <i>R</i> ,6 <i>R</i> )-2 $\alpha$ -Amino-4 $\alpha$ -fluorobicyclo [3.1.0]-hexane-2,6-dicarboxylic acid, [3,4-H-3(2)]	2004	47	9	571–581
7-(3'-Ammoniopropyl)-7,8-dicarba- <i>nido</i> -undecaborate(-1), [I-125] substitution in	2004	47	9	557–569
Arsenobetaine bromide, [C-14]	2004	47	7	393–397
Angiorufone and 4'-methoxy, [C-13]-labelled	2004	47	2	147–159
4-[2-((2 <i>S</i> )-Azetidinyloxy)]-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1 <i>H</i> -(6-hydroquinolyl)]-6-carboxamide, <i>N</i> -(pyrimidin-4-yl), [carboxyl-C-14]	2003	46	10	993–1000
4-((2 <i>S</i> )-Azetidin-2-yl)ethoxy]-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1 <i>H</i> -(6-hydroquinolyl)-6-carboxylic acid, [carboxyl-C-14]	2003	46	10	993–1000
4-[2-((2 <i>S</i> )-Azetidinyloxy)]-7-chloro-2-oxo-3-(3,4,5-trimethoxyphenyl)-1 <i>H</i> -(6-hydroquinolyl)]-6-carboxamide, <i>N</i> -(1,2,5-thiadiazol-3-yl), [carboxyl-C-14]	2003	46	10	993–1000
( <i>R</i> )-3-Azido-1-phenyl-1-[2-methylphenoxy] propane, [I-C-14]	2004	47	9	615–625
<b>B</b>				
Benzaldehydes, [7-C-14(1)]	2004	47	1	31–36
Benzoxazole, [3a,4,5,6,7,8-C-13(6)]	2004	47	1	19–24
(7 <i>aS</i> ,8 <i>aR</i> )-4-Benzyl-8-([C-13, H-2(3)]-methyl)-7,7 <i>a</i> ,8,8 <i>a</i> -tetrahydroazireno[2,3- <i>c</i> ]-imidazo [4,5,1- <i>ij</i> ]quinolin-5(4 <i>H</i> )-one	2004	47	9	609–614
4-Bromofluorobenzene, [F-18]	2004	47	7	429–441

Compound	Year	Vol	Part	Pages
2-Bromofluoroethane, [F-18]	2003	46	13	1229–1240
4-(2-( <i>N</i> - <i>t</i> -Butoxycarbonyl)-(2 <i>S</i> )-azetidin-2-yl)ethoxy-7-chloro-3-(3,4,5-trimethylphenyl)-1 <i>H</i> -quinolin-2-one-6-carboxylic acid, [carboxyl-C-14]	2003	46	10	993–1000
1-[4-(2-( <i>N</i> - <i>t</i> -Butoxycarbonyl)-(2 <i>S</i> )-azetidin-2-yl)ethoxy-7-chloro-3-(3,4,5-trimethylphenyl)-1 <i>H</i> -quinolin-2-one-6-carboxamide, <i>N</i> -pyrimidin-4-yl, [carboxyl-C-14]	2003	46	10	993–1000
<b>C</b>				
2-Chloro-([2-C-14]-acetamide), <i>N,N</i> -diethyl	2004	47	6	349–357
6-Chloro-3-[(2-( <i>S</i> )-azetidiny)methoxy]-5-[( <i>E</i> )-2-(2-fluoropyridin-4-yl)vinyl]pyridine, <i>also</i> NIDA, [F-18]	2004	47	6	385–392
( <i>S</i> )-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-[[F-18]-fluoro]-6-(trifluoromethyl)-1 <i>H</i> -indol-2-one	2003	46	12	1161–1171
<i>N</i> -{4-(4-Chlorophenyl)butyl}- <i>N,N</i> -diethyl-(7-fluoroheptyl)-ammonium ion, [F-18], <i>also</i> Fluoroclofilium	2003	46	12	1151–1160
[3-[(2 <i>R</i> )-[(2 <i>R</i> )-(3-Chlorophenyl)-2-hydroxyethyl]amino]-propyl]-1 <i>H</i> -indol-7-yloxy)-([2-C-14]-acetic acid), <i>also</i> AJ-9677	2004	47	6	349–357
[3-[(2 <i>R</i> )-[(2 <i>R</i> )-(3-Chlorophenyl)-([2-C-14]-2-hydroxyethyl)amino]propyl]-1 <i>H</i> -indol-7-yloxy]-acetic acid), <i>also</i> AJ-9677	2004	47	6	349–357
( <i>R</i> )-3-Chloro-1-phenyl-1[2-methyl-4-( <i>tert</i> butoxycarbonyl)-phenoxy]propane, [1-C-14]	2004	47	9	615–625
( <i>R</i> )-3-Chlorostyrene oxide, [7-C-14]	2004	47	6	349–357
Clarithromycin, [ <i>N</i> -methyl-C-13]	2004	47	2	95–98
1,5-Cyclooctadienyliridium(I)pentane-2,4-dionate, catalyst for deuteration of aromatic systems	2003	46	13	1191–1204
Cyclosporin A, [H-3]	2004	47	7	407–414
<b>D</b>				
Deuterium exchange in C <sub>6</sub> H <sub>5</sub> X, Ir-mediated, ligand effects	2004	47	1	1–10
1,5-Diaryl-{{5-C-14(1)}-1,2,3-triazolines}	2004	47	1	31–36
[3,5-Dichlorobenzenesulfonamide, U-C-14] labelled VLA-4 antagonists	2004	47	2	115–125
1,4-Dihydro-2,6-dimethyl-4-(2-nitro-phenyl)-3,5-pyridinedicarboxylic acid, dimethyl ester, [C-13(2)]	2003	46	13	1177–1179
( <i>S</i> )-[(1,3-Dihydro-1,3-dioxo-2 <i>H</i> -isoindol-2-yl)-methyl]- <i>O,O</i> -dimethyl phosphorodithionate, [N-15]	2004	47	8	509–512
3,4-Dihydroxybenzaldehyde, [ <i>ring</i> -C-14]	2004	47	4	209–216

Compound	Year	Vol	Part	Pages
(3 <i>R</i> ,18 <i>R</i> /5 <i>S</i> ,5 <i>Z</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i> )-3,18-Dihydroxy-18-(benzoyloxy)eicosa-5,8,11,14-tetraenoic acid, [5,6,8,9,11,12,14,15-H-3(8)]	2004	47	1	11–17
( <i>S</i> )-[(1,3-Dihydro-1,3-dioxo-2 <i>H</i> -isoindol-2-yl)-methyl]- <i>O</i> , <i>O</i> -dimethyl phosphorodithionate, [N-15]	2004	47	8	509–512
<i>N,N</i> -Di-isopropylethanamide, [2-H-2(1)], and analogues	2003	46	11	1033–1053
1,8- <i>bis</i> -(Dimethylamino)naphthalene—HF, [F-18], as source of nucleophilic halide ion	2004	47	6	373–383
1,1-Dimethylethanol, [1-C-11(1)]	2003	46	11	1075–1085
Diphenylthiocarbazide, [thiocarbonyl-C-14]	2003	46	12	1173–1176
Dithizone, [thiocarbonyl-C-14]	2003	46	12	1173–1176
<b>E</b>				
Enterodiol, [2,4,5,6,9,9,2',4',5',6'-H-2(10)]	2004	47	1	25–30
Enterolactone, [2,4,5,6,2',4',5',6'-H-2(8)]	2004	47	1	25–30
Estramustine and phosphate, [2,4,16,16,17-H-2(5)]	2004	47	2	161–165
Estromustine, [2,4,16,16-H-2(4)]	2004	47	2	161–165
2-[2-Ethoxy-5-(4-ethyl-4-oxidopiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3 <i>H</i> -[[2-C-14]imidazo][5,1- <i>f</i> ][1,2,4]-triazin-4-one	2003	46	11	1019–1032
2-[2-Ethoxy-5-(4-ethylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3 <i>H</i> -imidazo [5,1- <i>f</i> ][1,2,4]triazin-4-one hydrochloride <i>also</i> Vardenafil, [C-14]	2003	46	11	1019–1032
2-[2-Ethoxy-5-(4-ethylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3 <i>H</i> -imidazo [5,1- <i>f</i> ][1,2,4]triazin-4-one hydrochloride <i>also</i> Vardenafil, [H-3]	2003	46	13	1241–1247
2-[2-Ethoxy-5-(4-ethylpiperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3 <i>H</i> -[[2-C-14]imidazo][5,1- <i>f</i> ][1,2,4]-triazin-4-one	2003	46	11	1019–1032
4-Ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydro[[2-C-14]imidazo][5,1- <i>f</i> ][1,2,4]-triazin-2-yl) benzenesulfonyl chloride, and derivatives	2003	46	11	1019–1032
2-[2-Ethoxyphenyl]-5-methyl-7-propyl-3 <i>H</i> -[[2-C-14]imidazo][5,1- <i>f</i> ][1,2,4]-triazin-4-one	2003	46	11	1019–1032
2-[2-Ethoxy-5-(piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3 <i>H</i> -[[2-C-14]imidazo][5,1- <i>f</i> ][1,2,4]-triazin-4-one	2003	46	11	1019–1032
Ethyl 8-fluoro-5-[[F-18]-2-fluoroethyl]-6-oxo-5,6-dihydro-4 <i>H</i> -benzo[ <i>f</i> ]imidazo[1,5- <i>a</i> ][1,4]-diazepine-3-carboxylate	2003	46	13	1229–1240
<b>F</b>				
FK-506, [H-3]	2004	47	7	407–414
Flumazenil, [F-18] labelled derivs.	2003	46	13	1229–1240

Compound	Year	Vol	Part	Pages
(1 <i>R</i> ,2 <i>S</i> ,4 <i>R</i> ,5 <i>R</i> ,6 <i>R</i> )-2-(9 <i>H</i> -Fluoren-9-ylmethoxy-carbonyl)-4 $\alpha$ -fluoro-bicyclo[3.1.0]-hexane-2,6-dicarboxylic acid, [3,4- <i>H</i> -3(2)], diethyl ester	2004	47	9	571–581
(1 <i>R</i> ,2 <i>S</i> ,4 <i>R</i> ,5 <i>R</i> ,6 <i>R</i> )-2-(9 <i>H</i> -Fluoren-9-ylmethoxy-carbonyl)-4 $\alpha$ -hydroxy-bicyclo[3.1.0]-hexane-2,6-dicarboxylic acid, [3,4- <i>H</i> -3(2)], diethyl ester	2004	47	9	571–581
4-Fluorobenzaldehyde, [F-18]	2004	47	8	468–478
<i>N</i> -([F-18]-4-Fluorobenzyl-2-bromoacetamide in labelling of oligonucleotides)	2003	46	12	1093–1103
<i>N</i> -([F-18]-4-Fluorobenzyl-2-bromoacetamide in labelling of oligonucleotides (spiegelmers))	2003	46	13	1205–1219
4-Fluorobenzyltriarylphosphonium ions, [F-18]	2004	47	8	469–476
5-Fluoro-5'-deoxyadenosine, [F-18], enzymatic synth.	2003	46	13	1181–1189
2-Fluoroethylation, [F-18], <i>N</i> - and <i>O</i> -labelling	2004	47	5	289–297
<i>N</i> -(2-Fluoroethylation) of anilines, [F-18], through <i>N</i> -(haloacetyl)anilides	2004	47	4	217–232
{[F-18]-2-Fluoroethyl} 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4 <i>H</i> -benzo[ <i>f</i> ]imidazo[1,5- <i>a</i> ][1,4]-diazepine-3-carboxylate	2003	46	13	1229–1240
2-Fluoroethyl tosylate, [F-18], for <i>N</i> - and <i>O</i> -labelling under microwave conditions	2004	47	5	289–297
7-Fluoro-gingolide B, [F-18]	2004	47	8	485–491
1-(3-Fluoro-2-hydroxypropyl)-2-nitroimidazole, [F-18], also Fluoromisonidazole	2004	47	1	37–45
4-Fluoroiodobenzene, [F-18], improved synth.	2004	47	8	457–468
4-Fluorophenol, [F-18], synth., and diaryl ethers	2004	47	7	443–455
2-(4-Fluorophenyl)benzimidazole, [F-18]	2004	47	2	139–145
5-(4'-Fluorophenyl)-2'-deoxyuridine, [F-18]	2004	47	8	457–468
5-(4'-Fluorophenyl){1-{2-(2-iodophenyl)ethyl}piperidin-4-yl}methanone, [I-123]	2004	47	9	591–598
( <i>S</i> )-1-(4-Fluorophenyl)-1-(3-methylaminopropyl-[3- <i>H</i> -2(2)])-1,3-dihydro-isobenzofuran-5-carbonitrile	2004	47	6	335–348
5-(4'-Fluorophenyl)uridine, [F-18]	2004	47	8	457–468
3-[1-(3-Fluoropropyl)-( <i>S</i> )-pyrrolidin-2-ylmethoxy]-pyridine, [F-18]	2003	46	14	1261–1268
3-Fluoropropyltriarylphosphonium ions, [F-18]	2004	47	8	469–476
2-, 3-, and 4-Fluoropyridine, [F-18], n.c.a. prep	2003	46	10	979–992
4-([F-18]-Fluoro)- <i>N</i> -{2-[4-(6-trifluoromethylpyridin-2-yl)-piperazin-1-yl]ethyl}benzamide	2004	47	9	531–542
Fluticasone propionate, [F-18], in Flixotide inhalers	2004	47	1	55–70
<b>G</b>				
[Ga-68]-labelling of oligonucleotides, microwave accelerated	2004	47	1	79–89

Compound	Year	Vol	Part	Pages
<b>H</b>				
Hexamethyl disiloxane, [O-18]	2003	46	11	1001–1005
4-Hydroxybenzaldehyde, [ring-C-14]	2004	47	4	209–216
2-Hydroxybenzotrile, [7-C-14(1)]	2003	46	11	1019–1032
(3 <i>R</i> ,18 <i>R</i> / <i>S</i> ,5 <i>Z</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i> )-3-Hydroxy-18-(benzoyloxy)-eicosa-5,8,11,14-tetraenoic acid, [5,6,8,9,11,12,14,15-H-3(8)]	2004	47	1	11–17
1-(4-Hydroxy-3,5-diiodobenzyl)-3-(1-[2-(3-methyl-3 <i>H</i> -diazirin-3-yl)-ethyl]-2,3-dihydro-1 <i>H</i> -benzoimidazol-2-ylmethyl)-1,3-dihydrobenzoimidazol-2-one, [I-125]	2003	46	12	1105–1116
(3 <i>R</i> ,5 <i>Z</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i> )-3-Hydroxyeicosa-5,8,11,14-tetraenoic acid, [5,6,8,9,11,12,14,15-H-3(8)]	2004	47	1	11–17
1-(4-Hydroxy-3-iodobenzyl)-3-(1-[2-(3-methyl-3 <i>H</i> -diazirin-3-yl)-ethyl]-2,3-dihydro-1 <i>H</i> -benzoimidazol-2-ylmethyl)-1,3-dihydrobenzoimidazol-2-one, [I-125]	2003	46	12	1105–1116
4-Hydroxy-3-methoxybenzaldehyde, [ring-C-14]	2004	47	4	209–216
Hypericin, mono- and di-iodination of, [I-123]	2004	47	3	191–198
<b>I</b>				
1-(Indole-6-carbonyl-D-phenylglyciny)-4-(1-methylpiperidin-4-yl)piperazine, [carbonyl-C-14], <i>also</i> LY517717-[C-14]	2004	47	9	599–608
<i>N</i> -([I-125]-4-Iodobenzyl-2-bromoacetamide in labelling of oligonucleotides (spiegelmers)	2003	46	13	1205–1219
( <i>R</i> )-3-Iodo-1-phenyl-1[2-methyl-4-( <i>tert</i> butoxycarbonyl)-phenoxy]propane, [1-C-14]	2004	47	9	615–625
Iptakalim, [1,2-H-3(2)]	2004	47	9	583–590
Iptakalim, [H-2(7)]	2004	47	9	583–590
Iridium complexes in directed deuteriations	2003	46	13	1191–1204
<b>J</b>				
<b>K</b>				
<b>L</b>				
Lachnanthocarpone, [phenyl-C-13(6)]	2004	47	2	147–159
<b>M</b>				
Methane, [C-11;H-2(4)]	2004	47	6	335–348
Methanesulfinyl chloride, [O-18]	2003	46	11	1001–1005
Methanesulfonyl chloride, [C-11], synth.	2003	46	12	1127–1140
Methanol, [C-11], esterification with	2004	47	8	523–530
(5 <i>R</i> )-5-([C-13, H-2(3)]-Methyl)amino-5,6-dihydro-4 <i>H</i> -imidazo[4,5,1- <i>ij</i> ]quinolin-2(1 <i>H</i> )-one, <i>also</i> PNU-95666E	2004	47	9	609–614
2-(4-{[C-11]-Methyl}aminostyryl)-5-fluorobenzoxazole	2004	47	3	181–190

Compound	Year	Vol	Part	Pages
2-(4-Methylaminostyryl)-6-(2-fluoroethoxy)benzoxazole, [F-18]	2004	47	3	181–190
{[5-C-11]-Methyl}-1-aza-5-stannabicyclo[3.3.3]undecane	2004	47	1	71–78
( <i>S</i> )-(N-Methyl-[C-11])citalopram	2004	47	6	335–348
( <i>S</i> )-(N-Methyl-[C-11])citalopram, [ $\alpha$ -H-2(2)]	2004	47	6	335–348
( <i>S</i> )-(N-Methyl-[C-11; H-2(3)])citalopram	2004	47	6	335–348
{[C-11]-N-Methyl}-3-(6-dimethylamino-3-pyridyl)-2,5-dimethyl-N,N-dipropylpyrazolo[1,5- <i>a</i> ]pyrimidin-7-amine, also R121920	2003	46	11	1055–1065
1,1'-([C-14]-Methylene)-di-(2-naphthol)	2004	47	9	541–556
Methyl esters, [C-11], with BF <sub>3</sub> or Me <sub>3</sub> SiCl as enhancers	2004	47	8	523–530
{[1,2-H-3(2)]-Methylethyl}-3-(1-[2-(3-methyl-3 <i>H</i> -diazirin-3-yl)-ethyl]-1 <i>H</i> -benzoimidazol-2-ylmethyl)-1,3-dihydrobenzoimidazol-2-one	2003	46	12	1105–1116
1-([C-11]-1-Methylethyl)-4-phenylpiperazine	2003	46	11	1075–1085
([H-3]-Methyl)-galanthamine iodide	2003	46	12	1117–1125
Methyl iodide, [C-11]	2003	46	12	1127–1140
Methyl iodide, [C-11]	2003	46	13	1221–1228
Methyl iodide, [C-13, H-2(3)]	2004	47	6	335–348
<i>N</i> -{[C-11]-Methyl}-methylene blue, synth.	2003	46	13	1221–1228
( <i>R</i> )- <i>N</i> -Methyl-3-[2-methylphenoxy]-3-phenylpropanamine, [3-C-14], also LY130603	2004	47	9	615–625
(3 <i>R</i> )-[2-Methylphenoxy]-3-phenylpropanamine, [3-C-14]	2004	47	9	615–625
2-Methyl-2-propanol, [2-C-11], synth.	2003	46	11	1075–1085
6-(Methylseleno)- <i>N</i> <sup>6</sup> -cyclopentyladenosine, [Se-75]	2004	47	7	415–427
2-Methyltetralone, <i>C</i> -deuteration of, using piperidine-[H-2(11)]	2004	47	6	359–371
Methyl triflate, [C-11]	2003	46	11	1055–1065
Methyl triflate, [C-11]	2003	46	13	1221–1228
<b>N</b>				
2-(2-Naphthalenyl)-4,5-dihydro-1 <i>H</i> -([2-C-11]-imidazole), also benazoline	2003	46	12	1141–1149
Neurokinin-1 receptor ligands, [H-3 labelled]	2004	47	2	99–106
Nitromethane, [C-11]	2003	46	14	1279–1285
1-Nitro-4-phenylbutan-2-ol, [1-C-11]	2003	46	14	1279–1285
NN414, [C-14, C-13, or H-2 labelled]	2004	47	2	127–138
<b>O</b>				
<b>P</b>				
[3,7,8-N-15(3)]- <i>N</i> <sup>1</sup> -( $\beta$ -D- <i>erythro</i> -Pentofuranosyl)-5-guanidinohydantoin	2003	46	14	1269–1277

Compound	Year	Vol	Part	Pages
Phenylphenalenones, [C-13] labelling	2004	47	2	147–159
Phosmet, [N-15]	2004	47	8	509–512
2-Propanone, [2-C-11], synth. and reductive alkylation of amines by	2003	46	11	1075–1085
<b>Q</b>				
<b>R</b>				
Resveratrol, [β-C-14]	2004	47	3	167–174
<b>S</b>				
<i>Streptomyces cattleya</i> catalysed enzymatic [F-18]-fluorination	2003	46	13	1181–1189
Sulforaphane, [1,1,2,2,3,3,4,4-H-2(8)]	2004	47	8	501–507
<b>T</b>				
[Tc-99 m]-CO-MIBI complex	2004	47	8	513–521
[Tc-99 m]-ENS, quality control methods	2004	47	1	47–53
[Tc-99 m]-Techmazetil	2004	47	3	199–208
[Tc-99 m]-TRODAT-1	2003	46	11	1067–1073
[Tc-99 m]-L-Tyrosine deriv.	2004	47	8	477–483
2,3,4,9-Tetrahydro-1 <i>H</i> -carbazoles, [H-3 labelled]	2004	47	2	107–113
1-( <i>D</i> -1,2,3,4-Tetrahydroisoquinoline-3-carboxy- <i>D</i> -[4-iodo-phenylalanyl])-4-cyclohexyl-4-[(1,2,4-triazol-1-yl)methyl]piperidine trifluoroacetate, [I-125]	2003	46	11	1007–1017
( <i>R</i> )-(N-{1,2,3,4-Tetrahydro-5-methyl-8-(4-methylpiperazin-yl)-2-naphthyl}-4-morpholino-benzamide, [carbonyl-C-14])	2004	47	3	175–180
( <i>R</i> )-(N-{1,2,3,4-Tetrahydro-5-methyl-8-(4-methylpiperazin-yl)-2-naphthyl}-4-morpholino-benzamide, [7-H-3(1)])	2004	47	3	175–180
α,α,α-Trifluoromethyl ketones, [1-F-18(1)], synth.	2003	46	11	1087–1092
3,4',5-Trihydroxy- <i>trans</i> -stilbene, [β-C-14]	2004	47	3	167–174
3,4',5-Trimethoxy- <i>trans</i> -stilbene, [β-C-14]	2004	47	3	167–174
1,1,2-Trimethylpropanamine, <i>N</i> -([H-2(7)-1-methylethyl]), <i>also</i> Iptakalim, [H-2(7)]	2004	47	9	583–590
<b>V</b>				
Vardenafil, [C-14]	2003	46	11	1019–1032
Vardenafil, [H-3]	2003	46	13	1241–1247
<b>W</b>				
<b>X</b>				

Compound	Year	Vol	Part	Pages
<b>Y</b>				
<b>Z</b>				
Zaleplon, [H-3]	2002	45	11	911–915